Corcept Therapeutics Incorporated Stock 12‑Month Price Target Raised to $142.6, Implies 74% Upside

Analysts raised Corcept Therapeutics' (CORT) average price target to $142.6, up from $141, with a range of $50 to $173. This implies 74% upside from the Nov. 3 close. The consensus rating is 'Buy' from 7 analysts, with 5 Buys, 1 Hold, and 1 Sell.

Original reporting
Published Nov 4, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Corcept Therapeutics Incorporated Stock 12‑Month Price Target Raised to $142.6, Implies 74% Upside — source image
Decision brief

The 30-second read

Low
01

Why it matters

Analyst consensus remains a Buy, with a slight upward revision in price targets, indicating modest optimism.

02

Market read

The price‑target lift provides a mild bullish cue but lacks a decisive catalyst for immediate trading.

03

What to watch

Potential risks from clinical trial outcomes or regulatory decisions could offset the target raise.

Relevance 5/10Novelty 4/10Timing: today

Background

Corcept Therapeutics is a specialty pharmaceutical company focused on cortisol‑related therapies.

Market effects

Minimal; the change reflects analyst sentiment on Corcept rather than a sector‑wide shift.

Limited to US biotech/pharma investors.

Low; no broader macro or global impact.

Counterpoint

Some investors may view the modest target increase as already priced in, limiting upside.

Key entities

  • Corcept Therapeutics Incorporated

    US‑listed biotech firm (NASDAQ: CRCT).

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.